Centerline Biomedical joins ORSIF
Centerline Biomedical and ORSIF join together to raise awareness of health risks associated with fluoroscopic radiation and solutions available to medical professionals.
"We are proud to join ORSIF in its mission to create greater awareness in the medical community regarding the dangers of radiation exposure and to protect those who commit their lives to the wellness of others. To that end, IOPS® (Intra-Operative Positioning System) technology enables improved visualization with 3D navigation in endovascular procedures while minimizing the reliance on damaging radiation," said
Designed to mitigate radiation exposure during minimally invasive cardiovascular procedures, Centerline Biomedical IOPS (Intra-Operative Positioning System) is a novel technology gaining increased application in the US. IOPS includes software that creates 3D maps of vascular anatomy, enabling surgeons to visualize the arteries being treated. Using electromagnetic tracking, IOPS sensor-equipped guidewires and catheters can be guided in 3D as endovascular specialists navigate through these high-resolution intuitive visualizations during minimally invasive procedures. The images and tracking are displayed on an independent monitor, minimizing the reliance on damaging X-ray radiation typically used to produce live fluoroscopic images during interventions.
About Centerline Biomedical
Founded in 2015, Centerline Biomedical is headquartered in Cleveland,
Visit www.centerlinebiomedical.com for more information.
View original content to download multimedia:https://www.prnewswire.com/news-releases/centerline-biomedical-joins-orsif-302192349.html
SOURCE Centerline Biomedical
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DREYER'S GRAND ICE CREAM, INC. ISSUES VOLUNTARY RECALL ON SELECT OUTSHINE FRUIT BARS DUE TO POSSIBLE FOREIGN MATTER CONTAMINATION
- 3 Top Crypto to Buy Now While Fear Takes Over and One Presale Keeps Pulling in Millions
- APIC delivers 55% EBITDA growth in the first half of 2026, reaching USD 44 million
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share